GlassScriptPhysician profile
Miranda Wang-Gor
NPI 1821030065
$8,927.52
in general payments reported to CMS, 2019-2025
51 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,068 · 2020: $394 · 2021: $1,237 · 2022: $1,395 · 2023: $1,823 · 2024: $1,940 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,832.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,473.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $890.06 | 2021-2024 | Qulipta, Linzess, Vraylar |
| Astrazeneca Pharmaceuticals LP | $762.77 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $736.55 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $517.82 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $420.01 | 2022-2025 | |
| Amgen INC. | $370.08 | 2020-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $333.95 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.52 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Sanofi-Aventis U.S. LLC | $312.01 | 2019-2025 | |
| Corcept Therapeutics | $301.40 | 2021-2025 | Korlym |
| Merck Sharp & Dohme LLC | $258.13 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Exact Sciences Corporation | $231.73 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.97 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $125.67 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Wang-Gor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.